BeyondSpring, Inc. (BYSI)
Stock Price:
$14.12 USD
0.20 (1.44%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
425.26M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-38.09M |
| Shares Out |
30.12M |
| EPS (ttm) |
-1.93 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$14.12 |
| Previous Close |
$13.92 |
| Change ($) |
0.20 |
| Change (%) |
1.44% |
| Day's Open |
14.01 |
| Day's Range |
13.90 - 14.32 |
| Day's Volume |
27,312 |
| 52-Week Range |
9.38 - 21.50 |
More Stats
| Market Cap |
425.26M |
| Enterprise Value |
393.24M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
30.12M |
| Float |
13.26M |
| EPS (basic) |
-1.55 |
| EPS (diluted) |
-1.93 |
| FCF / Share |
-1.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
838,515 |
| Short Ratio |
5.46 |
| Short % of Float |
6.32% |
| Beta |
0.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
14.45 |
| Revenue |
n/a |
| Operating Income |
-40.31M |
| Net Income |
-38.09M |
| Free Cash Flow |
-48.17M |
| Net Cash |
32.03M |
| Net Cash / Share |
1.06 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-130.93% |
| ROE |
-814.58% |
| ROIC |
701.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$41.50*
(193.91% upside)
Low
37.0
Current: $14.12
High
46.0
Target: 41.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -40.31 | -57.23 | -97.06 | -12.37 | -7.50 | -2.11 |
| Net Income | -38.09 | -54.87 | -91.76 | -12.01 | -7.97 | -3.01 |
| Shares Outstanding | 24.65 | 22.67 | 20.87 | 16.09 | 15.17 | 13.91 |
| Earnings Per Share | -1.55 | -2.42 | -4.40 | -0.75 | -0.53 | -0.22 |
| Operating Cash Flow | -48.16 | -39.96 | -28.80 | -13.70 | -6.57 | -1.15 |
| Capital Expenditures | - | -0.21 | -0.08 | -0.06 | -0.04 | - |
| Free Cash Flow | -48.17 | -40.16 | -28.87 | -13.76 | -6.61 | -1.15 |
| Cash & Equivalents | 35.93 | 3.89 | 30.56 | 11.69 | 10.82 | - |
| Total Debt | 3.91 | - | - | - | - | - |
| Net Cash / Debt | 32.03 | 3.89 | 30.56 | 11.69 | 10.82 | - |
| Assets | 44.56 | 7.06 | 32.83 | 14.91 | 10.97 | - |
| Liabilities | 13.42 | 16.45 | 4.79 | 2.61 | 1.31 | - |
| Book Value | 30.28 | -7.77 | 27.08 | 12.15 | 8.95 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BeyondSpring, Inc. |
| Country |
United States |
| Employees |
61 |
| CEO |
Lan Huang |
Stock Information
| Ticker Symbol |
BYSI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BYSI |
| IPO Date |
March 9, 2017 |
Description
BeyondSpring, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.